Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?

Karel J. van Erpecum; Milan J. Sonneveld

doi:10.1016/j.ejim.2021.05.003

Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?

Karel J. van Erpecum^*
, Milan J. Sonneveld

^*Corresponding author for this work

Gastroenterology & Hepatology

University Medical Centre Utrecht

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

1 Citation (Scopus)

Original language	English
Pages (from-to)	27-29
Number of pages	3
Journal	European Journal of Internal Medicine
Volume	89
DOIs	https://doi.org/10.1016/j.ejim.2021.05.003
Publication status	Published - 1 Jul 2021

Bibliographical note

Funding Information:
KJvE declares no conflict of interest. MJS has received speaker's fees and research support from Roche, BMS, Gilead and Fujirebio.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1016/j.ejim.2021.05.003

http://www.ejinme.com/article/S0953620521001539/pdf

Cite this

@article{0bb8785b23f54ad181ff0c897d425e6c,

title = "Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?",

author = "\{van Erpecum\}, \{Karel J.\} and Sonneveld, \{Milan J.\}",

note = "Funding Information: KJvE declares no conflict of interest. MJS has received speaker's fees and research support from Roche, BMS, Gilead and Fujirebio.",

year = "2021",

month = jul,

day = "1",

doi = "10.1016/j.ejim.2021.05.003",

language = "English",

volume = "89",

pages = "27--29",

journal = "European Journal of Internal Medicine",

issn = "0953-6205",

publisher = "Elsevier",

}

Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred? / van Erpecum, Karel J.; Sonneveld, Milan J.
In: European Journal of Internal Medicine, Vol. 89, 01.07.2021, p. 27-29.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection

T2 - Is tenofovir or entecavir preferred?

AU - van Erpecum, Karel J.

AU - Sonneveld, Milan J.

N1 - Funding Information: KJvE declares no conflict of interest. MJS has received speaker's fees and research support from Roche, BMS, Gilead and Fujirebio.

PY - 2021/7/1

Y1 - 2021/7/1

UR - https://www.scopus.com/pages/publications/85106376713

U2 - 10.1016/j.ejim.2021.05.003

DO - 10.1016/j.ejim.2021.05.003

M3 - Comment/Letter to the editor

C2 - 34023149

AN - SCOPUS:85106376713

SN - 0953-6205

VL - 89

SP - 27

EP - 29

JO - European Journal of Internal Medicine

JF - European Journal of Internal Medicine

ER -

Antiviral therapy after curative treatment of hepatocellular carcinoma in patients with chronic hepatitis B infection: Is tenofovir or entecavir preferred?

Bibliographical note

UN SDGs

Access to Document

Other files and links

Cite this